Serum Amyloid a Attenuates Tau Phosphorylation in a Systemic Inflammation Model

Yang Yu,Jin Liu,Richard D. Ye
DOI: https://doi.org/10.1016/j.jalz.2015.06.1730
2015-01-01
Abstract:The major acute-phase protein Serum amyloid A (SAA) has been found regulate the inflammation and immunity response via chemoattracting monocytes and neutrophils and inducing cytokines release. In Alzheimer's disease (AD), the SAA concentration in CSF is much higher in AD subjects than in normal controls. SAA has also been found to colocalize with Aβdeposits based on immunocytochemical analysis in AD patient brain. These observations suggest that SAA may contribute to the progression of AD, but the exact role of SAA in AD is not known. A murine model of systemic inflammation by IP LPS was used in here. Tau phosphorylation was examined by Western blot. SAA expression and activation of glia cells were determined by IHC. We reported here that systemic LPS administration robustly induced Tau hyperphosphorylation and SAA expression in the mice brain. In the SAA deficiency mouse model, LPS induced Tau hyperphosphorylation was more higher compared to wild-type mice, but the impact of LPS was alleviated in SAA transgenic mice. Furthermore, intracranial SAA injection directly reduced Tau phosphorylation. These results suggest SAA performs a resistant effect on Tau hyperphosphorylation and SAA may play a protective role in AD pathology.
What problem does this paper attempt to address?